Intralesional interferon-α for conjunctival mucosa-associated lymphoid tissue lymphoma: long-term results.

摘要: Objective To report the long-term therapeutic results for patients with conjunctival mucosa-associated lymphoid tissue (MALT) lymphoma who were treated intralesional injections of interferon-α (IFN-α). Design Prospective, nonrandomized, interventional case series. Participants Twenty eyes 16 histologically proven MALT in absence systemic disease. Methods Patients given 1 500 000 international units (IU) IFN-α (Roferon-A; Roche s.p.a., Milano, Italy) subconjunctivally inside lesion 3 times weekly 4 weeks. If there was even a minimal response, further cycle IU weeks administered. Main Outcome Measures followed up clinically using slit-lamp examination to determine evidence tumor disappearance or recurrence. In 10 eyes, an incisional biopsy performed 6 months after therapy verify histologic lesion. Results A complete response obtained 15 (75%) at end first treatment, and 5 (25%) cycles. Seventeen (85%) showed no local recurrence median follow-up 65 (range, 15–136 months). Three (15%) demonstrated variable points treatment. One patient stage IIA exhibited progression. Conclusions Local immunotherapy seems be effective lasting treatment method provides alternative radiotherapy lymphomas. Very few transient side effects detected. Financial Disclosure(s) The author(s) have proprietary commercial interest any materials discussed this article.